Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, ...
Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular ...
Alnylam Pharmaceuticals' shares rose more than 10% on Friday after the drugmaker secured U.S. approval for its heart disease drug, setting the stage for the 23-year-old biotech's next phase of growth.
Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...
The FDA's approval of Alnylam's heart disease drug expands treatment options in a market poised for growth. Meanwhile, the ...
In emergency medical response scenarios, ROSC – the return of spontaneous circulation – refers to the restoration of a ...
A NURSE suffered a fatal cardiac arrest after being prescribed a fatal combination of three common drugs. Her sudden passing prompted an urgent warning to doctors dishing out the medications, over ...
Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback